Skip to main content
Erasca reports 44% pancreatic cancer response rate
Image for illustrative purposes only. Not a real photo.

Erasca reports 44% pancreatic cancer response rate

By

Key points

  • Erasca (NASDAQ:ERAS) reported a 44% confirmed objective response rate for its investigational ERAS-0015 drug in patients with previously treated KRAS G12X pancreatic cancer.
  • The response rate reached 69% among patients with KRAS G12D or G12V mutations and 60% in a small group of previously treated KRAS G12X lung cancer patients.
  • Erasca plans to start a Phase 3 pancreatic cancer trial and a potentially registration-enabling lung cancer trial in the first half of 2027, while advancing its second investigational drug, ERAS-4001.

Erasca (NASDAQ:ERAS) reported interim Phase 1 results showing a 44% confirmed objective response rate for its investigational drug ERAS-0015 in patients with previously treated KRAS G12X pancreatic cancer.

At a once-daily dose of 32 mg, the response rate reached 69% among 13 patients with KRAS G12D or G12V pancreatic cancer mutations, while a separate group of five patients with previously treated KRAS G12X non-small cell lung cancer recorded a 60% response rate.

"These compelling results highlight the strength and breadth of ERAS-0015's clinical activity across several tumor types," said Erasca Chairman, Chief Executive Officer and Co-founder Jonathan E. Lim.

Most treatment-related adverse events were low grade, with no treatment-related discontinuations at the 32 mg dose, although one previously reported case of pneumonitis at 24 mg progressed to a fatal event, with no additional fatal treatment-related events reported.

Erasca is also evaluating ERAS-0015 in combination with chemotherapy, pembrolizumab and panitumumab, reporting early tolerability data and antitumor responses in several solid tumour types, including KRAS-mutant colorectal cancer.

The company plans to accelerate its first-line pancreatic cancer Phase 3 trial to the first half of 2027 and start a potentially registration-enabling second-line or later lung cancer trial during the same period, while planning further ERAS-4001 combination studies in 2027.


Frequently asked questions